Singapore Bioinformatics Market Analysis Report 2022 to 2030

Singapore Bioinformatics Market Analysis

$ 3999

The Singapore Bioinformatics market is projected to grow from $18.42 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The main factors driving the growth would be strong research and development, the growing healthcare sector, an increase in demand for personalized medicine, and government support. The market is segmented by technology and by application. Some of the major players include Genomax (SGP), Illumina, Agilent Technologies, IBM Life Sciences, and Qiagen.

ID: IN10SGHS001 CATEGORY: Healthcare Services GEOGRAPHY: Singapore AUTHOR: Neha Davda

Buy Now

Singapore Bioinformatics Market Executive Summary

The Singapore Bioinformatics market is projected to grow from $18.42 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. In 2019, healthcare spending in Singapore was $2,633 per capita, a decline of 1.31% from the previous year. It spent 4.09% of its GDP on healthcare which was comparatively low to many other developed countries.

The field of bioinformatics combines the study of biology and information technology. Bioinformatics employs a variety of approaches, including data production, data warehousing, data mining, data management, and more. For applications like next-generation sequencing, modeling of genomic and proteomic structure, and three-dimensional drug discovery, bioinformatics software and tools are employed as integrated solutions to provide statistical approaches and data processing algorithms. In the upcoming years, the bioinformatics market in the Asia Pacific area is expected to rise significantly.

singapore bioinformatics market analysis

Market Dynamics

Market Growth Drivers

The Singapore bioinformatics market is expected to be driven by the factors such as strong research and development, a growing healthcare sector, and an increase in demand for personalized medicine. Moreover, the government has also made significant investments in the bioinformatics field of the life sciences through Bioinformatics Institute (BII) and programs like the Biomedical Research Council and the Biomedical Research Infrastructure Scheme. In addition to creating a strong talent pool, this has assisted in luring several bioinformatics businesses to the nation.

Market Restraints

Development and commercialization of bioinformatics technology are costly and high labor, rent, and electricity expenses in Singapore can be a barrier for SMEs. Further, Singapore's domestic market for bioinformatics is relatively young and small along with the absence of industry standardization, it can be challenging for businesses to create and promote their products

Competitive Landscape

Key Players

Genomax (SGP)
Illumina
Agilent Technologies
IBM Life Sciences
Qiagen

Healthcare Policies and Regulatory Landscape

The Ministry of Health (MOH) and the Health Sciences Authority (HSA) are in charge of overseeing the healthcare industry in Singapore. The MOH establishes rules and standards for the provision of healthcare, whereas the HSA is in charge of overseeing the registration and licensing of healthcare goods and services.

The Agency for Science, Technology, and Research (ASTAR) and the National University of Singapore (NUS) are important stakeholders in the growth and promotion of bioinformatics research and innovation in Singapore. For instance, the Genome Institute of Singapore, which is part of ASTAR, carries out bioinformatics and genomics research and offers bioinformatics services to academics and businesses.

Reimbursement Scenario

In Singapore, the Ministry of Health (MOH) and the Medisave program are primarily responsible for setting reimbursement policies. A national savings program called Medisave enables people to set aside a percentage of their salary to cover medical costs for themselves and their families. Although Medisave can be used for a variety of medical costs, such as hospital stays and day surgeries, it does not fully cover these costs.

Medisave can be used to pay for specified genetic testing services that have been authorized by the Ministry of Health in terms of bioinformatics. This covers specific cancer-related genetic tests as well as genetic testing for some inherited medical diseases including thalassemia. The government has also developed other programs like the Medishield Life and ElderShield schemes, which are meant to help people with specific medical illnesses or impairments financially.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Bioinformatics Market Segmentation

By Technology (Revenue, USD Billion):

Knowledge Management Tools
Bioinformatics Platforms
Bioinformatics Services

By Application (Revenue, USD Billion):

Metabolomics
Molecular phylogenetics
Transcriptomics
Chemoinformatic & drug design
Genomics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.